USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Growth Opportunities in the Biologics Contract Development and Manufacturing Organization Sector
Growth Opportunities in the Biologics Contract Development and Manufacturing Organization Sector
Value Chain Expansion to Support Next generation Biologics Drives Future Growth Potential
10-May-2023
Global
Description
This research service provides an overview of the global biologics contract development and manufacturing organization (bio-CDMO) market
and a 6-year market revenue forecast (2023 to 2028). The geographic scope covers three key regions, namely North America (NA); Europe;
and Asia-Pacific (APAC). The report offers a detailed segment analysis of the bio-CDMO market, including emerging business models such as reserved capacity and contract research development and manufacturing organization (CRDMO) services that are set to dominate the traditional
fee-for-service manufacturing services space. The market segments cover drug type (drug substance and drug products) and cell expression type (microbial, mammalian, and other modalities). The other modalities segment includes cell-free expression systems, such as nucleic acid-based products and insect- and plant-based expression systems. For the purpose of this study, the bio-CDMO market forecast includes services encompassing drug development and manufacturing processes, such as product development (R&D) services, analytical support, and
manufacturing and packaging services, into one integrated process (from drug development through manufacturing).
The industry shift toward biologics is boosting product pipelines and adoption, leading to more demand for biologics manufacturing capability
and capacity expansion. Also, emerging biopharma companies hold two-thirds of the molecules in the R&D pipeline but have limited muscle to develop and commercialize these products. Bio-CDMOs can provide the agility and flexibility required for next-generation modalities such as CGT as they can use their modular facilities for multiple products and clients, which is a challenge for biopharma companies that build capabilities in-house. Big pharma is, therefore, increasingly choosing to outsource complex development and manufacturing processes and de-risking their supply chain instead of building more in-house manufacturing capacity. The transition of CDMOs to CRDMOs is leading them to offer end-to-end services. This positions competitors to partner with biopharmaceutical companies for their research, development, and manufacturing needs—from discovery to commercialization. While the COVID-19 pandemic has led to drug supply shortages, the pharmaceutical industry in general is moving toward right shoring, which involves keeping parts of the supply chain and processes in strategic locations to deliver the desired combination of cost and efficiency. CDMOs are playing a critical role in achieving supply chain resiliency.
Author: Surbhi Gupta
RESEARCH: INFOGRAPHIC
This infographic presents a brief overview of the research, and highlights the key topics discussed in it.Click image to view it in full size
Table of Contents
Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top Three Strategic Imperatives on the Global Biologics Contract Development and Manufacturing Organization (Bio-CDMO) Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Scope of Analysis
Market Segmentation by Product Type
Market Segmentation by Cell Expression System Type
Market Segmentation by Service Type
Key Regional Competitors in the Bio-CDMO Market
Growth Drivers
Growth Restraints
Biologics Pipeline Overview
Bio-CDMO Business Model—Value Chain Expansion
Overview of Key CDMO Activities to Support the Next-gen Biologics Modalities Driving Precision Medicine
Impact of Biosimilar Launches on CDMOs
Key Emerging Trends in the Bio-CDMO Industry
Key Emerging Trends in the Bio-CDMO Industry (continued)
New Modalities Paving the Way for New Entrants
New Modalities Paving Way for New Entrants
Product Distribution of Marketed Biologics in 2022
Distribution of Bioprocessing Technique—Single-use Bioreactors (SUB) and Fixed Multiuse Bioreactors (MUB) for Mammalian-based Manufacturing
Regional Distribution of Total Biomanufacturing Capacity
Key Growth Metrics for the Global Bio-CDMO Market
Forecast Framework—Bio-CDMO Market Sizing
Forecast Methodology—Bio-CDMO Market
Forecast Assumptions and Considerations—Bio-CDMO Market
Revenue Forecast—Global Bio-CDMO Market
Revenue Forecast Analysis—Global Bio-CDMO Market
Revenue Forecast by Product Type
Revenue Forecast Analysis by Product Type
Revenue Forecast by Cell Expression System Type
Revenue Forecast Analysis for Mammalian Expression Systems
Revenue Forecast Analysis for Microbial Expression Systems
Revenue Forecast Analysis for Other Expression Systems
Revenue Split by Service Type
Competitive Environment
Revenue Share Estimation—Top Bio-CDMO Market Participants
Revenue Share Analysis—Top Bio-CDMO Market Participants
Growth Opportunity 1: Building CGT Manufacturing and Distribution Capabilities in Europe
Growth Opportunity 1: Building CGT Manufacturing and Distribution Capabilities in Europe (continued)
Growth Opportunity 2: Improving and Expanding Viral Vector Manufacturing Capabilities in Asia
Growth Opportunity 2: Improving and Expanding Viral Vector Manufacturing Capabilities in Asia (continued)
Growth Opportunity 3: Live Biotherapeutic Products (Microbiome) Manufacturing Capabilities
Growth Opportunity 3: Live Biotherapeutic Products (Microbiome) Manufacturing Capabilities (continued)
Growth Opportunity 4: Adoption of AI and Digital Twins in Biomanufacturing
Growth Opportunity 4: Adoption of AI and Digital Twins in Biomanufacturing (continued)
Growth Opportunity 5: Discovery and Preclinical Services for New Modalities
Growth Opportunity 5: Discovery and Preclinical Services for New Modalities (continued)
Growth Opportunity 6: Purpose-built PAT Services for CGT
Growth Opportunity 6: Purpose-built PAT Services for CGT (continued)
Your Next Steps
Why Frost, Why Now?
List of Exhibits
Legal Disclaimer
Popular Topics
| Author | Surbhi Gupta |
|---|---|
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Keyword 1 | biologics contract manufacturing |
| Keyword 2 | Biologics CDMO Market |
| Keyword 3 | biologics industry |
| Podcast | No |
| Predecessor | MG0C-01-00-00-00 |
| WIP Number | PDEF-01-00-00-00 |